Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.

Abstract

BACKGROUND AND OBJECTIVE:

Atogepant is the latest calcitonin gene-related peptide (CGRP) antagonist approved exclusively for prophylaxis of episodic migraine and is administered orally in doses of 10-60 mg/day. This article aims to provide a systematic review of the efficacy and safety of atogepant in migraine prevention.

METHODS:

The literature was searched in different databases, i.e., the National Institute of Health clinical trials registry, PubMed, and the Cochrane library between 2018 to October 2021 using the keywords atogepant, MK-8031, and migraine. Conference abstracts listed in the Cochrane database (includes Embase) and drug information provided by the US Food and Drug Administration (FDA) label were also reviewed. Only English-language clinical trials were included. The authors retrieved 58 articles. Eventually, two randomized, double-blind, multicenter clinical trials involving 1,727 participants and one open-label trial were analyzed.

RESULTS:

The FDA approved atogepant for migraine prevention in September 2021 based on two randomized, double-blind, placebo-controlled trials. Atogepant approved for migraine prevention acts as a CGRP receptor antagonist and is administered orally. Based on the 12-week clinical trials, atogepant was efficacious in prevention of migraine and it was well tolerated. The most common treatment-emergent adverse events were nausea, constipation, and upper respiratory infection.

RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE:

Atogepant had a statistically significant change from baseline in monthly migraine days, monthly headache days, and acute medication use days.

CONCLUSIONS:

Atogepant seems to be beneficial for migraine prevention, and it may be of more benefit in individuals who do not wish to take the drug as an injection or do not require a prolonged duration of drug effect. However, head-to-head trials with other CGRP antagonists are required to ascertain its place in migraine prevention.

• Authors: Alok Singh, Mahesh Kumar Balasundaram
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 42 Issue 4 Pg. 301-308 (Apr 2022) ISSN: 1179-1918 [Electronic] New Zealand
• PMID: 35230651 (Publication Type: Systematic Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Analgesics
• Piperidines
• Pyridines
• Pyrroles
• Spiro Compounds
• atogepant
• Calcitonin Gene-Related Peptide

Topics

• Analgesics (therapeutic use)
• Calcitonin Gene-Related Peptide
• Double-Blind Method
• Headache
• Humans
• Migraine Disorders (drug therapy, prevention & control)
• Multicenter Studies as Topic
• Piperidines
• Pyridines
• Pyrroles
• Randomized Controlled Trials as Topic
• Spiro Compounds
• Treatment Outcome